|
gptkbp:instanceOf
|
peptide
immunosuppressant drug
|
|
gptkbp:approvedBy
|
1983 (US)
|
|
gptkbp:ATCCode
|
L04AD01
|
|
gptkbp:bioavailability
|
30% (oral)
|
|
gptkbp:brand
|
gptkb:Gengraf
gptkb:Sandimmune
gptkb:Neoral
|
|
gptkbp:CASNumber
|
59865-13-3
|
|
gptkbp:chemicalClass
|
cyclic undecapeptide
|
|
gptkbp:contraindication
|
uncontrolled hypertension
malignancy
hypersensitivity to ciclosporin
|
|
gptkbp:discoveredBy
|
gptkb:Jean-François_Borel
|
|
gptkbp:discoveredIn
|
1971
|
|
gptkbp:eliminationHalfLife
|
8.4 hours
|
|
gptkbp:hasMolecularFormula
|
C62H111N11O12
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ciclosporin
|
|
gptkbp:interactsWith
|
gptkb:rifampicin
gptkb:milk
gptkb:phenytoin
gptkb:ketoconazole
gptkb:St._John's_wort
|
|
gptkbp:KEGGID
|
D00137
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
immunosuppressant
|
|
gptkbp:MedlinePlusID
|
a601207
|
|
gptkbp:MeSH_ID
|
D003023
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
1202.61 g/mol
|
|
gptkbp:origin
|
Tolypocladium inflatum (fungus)
|
|
gptkbp:patent
|
gptkb:Sandoz
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
90%
|
|
gptkbp:PubChem_CID
|
5284373
DB00091
CHEMBL1373
|
|
gptkbp:routeOfAdministration
|
oral
topical
intravenous
|
|
gptkbp:sideEffect
|
hypertension
tremor
nephrotoxicity
hirsutism
gingival hyperplasia
|
|
gptkbp:UNII
|
83HN0GTJ6D
|
|
gptkbp:usedFor
|
prevention of organ transplant rejection
treatment of psoriasis
treatment of rheumatoid arthritis
treatment of atopic dermatitis
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
included
|
|
gptkbp:bfsParent
|
gptkb:S01XA27
|
|
gptkbp:bfsLayer
|
7
|